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Conclusions: The IMA test rapidly detects brief episodes of ischemia during PCI. Ongo- 
ing work will determine the duration and extent of ischemia required to elevate IMA lev- 
els. This test may prove useful to detect patients early in the course of cardiac ischemia. 
suggest that newer blomarkers (CRP and BNP) may be useful to identify women with 
high-risk ACS. 
1048-99 Unexplained Troponin-I Elevations in Patients With 
Increased Left Ventricular Mass 
Shadi M. Hamwi, Arvind K. Sharma, Neil J. Weissman, Steven A. Goldstein, Sue Apple, 
Daniel A. Canes, Ellen E. Pinnow, Joseph Lindsay, Washington Hospital Center, 
Washington, DC 
Background: Elevated Troponin-I (Tn-I) is a known indicator of myocardial infarction. 
However, mild elevations of Tn-I are occasionally noted in the absence of overt myocar- 
dial ischemia. It has been suggested that increased left ventricular mass (LVM) is a 
cause of elevated Tn-I. We sought to further investigate the potential relationship 
between LVM and Tn-I. 
Methods: From a single tertiary hospital ws screened patients presenting for an 
echocardiogram. Patients with acute coronary syndrome, heart failure, ejection fraction 
~55%. pulmonary embolism, pericarditis. creatinine >2 mgldl and sepsis were excluded. 
LVM was calculated by Penn Convention formula using PD-guided M-mode echocardio- 
graphy. Tn-I serum level was measured using a standard immunometric assay (normal 
range O-0.06 ngiml). 
Results: We identified 74 p&ants: 36 with normal LVM and 36 with increased LVM 
(93r18.7 and 164t30.5 g/m’, pcO.001). Mean age was 63.4i15.9 yrs. There were 43 
(56.1%) females and 68 (91.9%) African Americans. Hypertension was less frequent in 
the normal LVM group as compared to the increased LVM group [24 (66.7%) vs 35 
(92.1%), p=O.O09], while other risk factors (age, gender, race, diabetes mellitus, smoking 
and hypercholesterolemia) were not significantly different. There was no ECG evidence 
of myocardial ischemia in any patient. No patient with a normal LVM had elevated Tn-I, 
while 9 patients (23.7%) with Increased LVM had Tn-I elevation (median 0, range O-0.06 
vs median 0.02, range O-O.25 ng/ml, p=O.O4). Of the 21 patients with increased LVM 
>I50 g/m*, 8 (38.1%) had elevated Tn-I. 
Conclusion: Patients with Increased LVM have significantly increased Tn-I levels as 
compared to patients with normal LVM. There appears to be a relationship between the 
extent of LVM increase and elevation of Tn-I. Therefore, mild elevation of Tn-I in the 
presence of left ventricular hypertrophy may be a normal finding. 
1048-114 Gender Differences in Cardiac Biomarkers in Patients 
With Unstable Angina and Non-ST Elevation Myocardial 
Infarction in TACTICS-TIM1 18 
Steohen D. Wiviott, Christopher P. Cannon, David A. Morrow, Marc S. Sabatine, Sabina 
A. Murphy, Nadir Rafai, Peter M. DiBattiste, C. Michael Gibson, Carolyn H. McCabe, 
Eugene Braunwald. Brigham and Women’s Hospital, Boston, MA 
Background: Diagnosis of coronary artery disease in women is more difficult due to 
lower diagnostic accuracy of non-invasive testing and electrocardiography. We sought to 
examine the relationship between gender and cardiac biomarkers in patients presenting 
with acute coronary syndromes (ACS). 
Methods: In TACTICS-TIMI 18 and TIMI II, biomarker samples were drawn at baseline 
and analyzed in the TIMI core laboratory. We examined the relationship between gender 
and levels of presenting biomarkers, and the relatlonship between gender, “positive’ 
biomarkers and outcome. 
Results: Among 1846 patients from TIMI 16. 34% were women. Mean levels of Tnl and 
TnT were lower in women (Tnl: 4.1 vs 6.3 nglml for men, p<.OOOl; TnT: 0.26 vs .39 ngl 
ml, p=O.Ol), whereas levels of hs-CRP and BNP were higher (CRP: 1.6 vs 1.3 mg/dl, 
pcO.05; BNP 66 vs 46 pglml, pc 0.0001). When examined using accepted cut points, 
fewer women had elevated troponins, while more had elevated CRP or BNP (Figure, 
p<.Ol for each). Presence of ST segment deviation, and TIMI risk scores were not signif- 
icantly different between genders. This pattern of biomarkers was confirmed in TIMI Il. 
Six-month mortality among patients with each positlve biomarker was similar for men and 
women 
Conclusions: In patients with non-ST elevation ACS, there was a different pattern oi 
biomarkers on admission between men and women. If prospectively validated, our data 
1048-115 Early Decreased Interleukin-6 but Persistently Elevated 
von Willebrand Factor During Long-Term Dalteparin 
Treatment in Unstable Coronary Artery Disease 
Jonas Oldaren, Lars Wall&in, Agneta Siegbahn. University Hospital, Uppsala, Sweden 
Background: Unstable coronary artery disease (CAD) is associated with an acute-phase 
response. Interleukin-6 (11-6) is present in the atherosclerotic plaque and IS secreted by 
both endothelial cells, smooth muscle cells and macrophages. van Willabrand factor 
(vWF). stored in endothelial cells and platelet granules, is rapidly released at the local 
site of the injured coronary artery and has a major role in platelet adhesion to exposed 
subendothelium. 
Methods: II-6 and vWF antigen were analyzed in serial samples from 556 out of the 2267 
patients with unstable CAD in the Scandinavian multicenter study FRISC II. All patients 
were treated with subcutaneous dalteparin 120 IU/kg twice dally for 5-7 days and then 
randomized to placebo (n=266) or long-term treatment with weight-adjusted doses of 
dalteparin (5000 or 7500 IU) twice daily (n=272) for three months. Follow-up was 3 
months after cessation of treatment. 
Results: See table. Data are medians and Mann-Whitney tests. 
Conclusion: The initially high levels of II-6 were early decreased, wth no differences 
between the groups in II-6 levels during long-term dalteparinlplacebo treatment. Patients 
randomized to placebo had a significant decrease in vWF levels after cessation of in-hos- 
pital dalteparin treatment. However, patients randomized to long-term dalteparin treat- 
ment had significantly higher vWF levels up to 3 months, followed by a significant 
decrease. This might contribute to the lack of efficacy by lopg-term dalteparin treatment 
in unstable CAD. 
11-6, rig/L P vWF, % P 
In-hospital: dalteparin 120 U/kg dalteparin 120 U/kg 
randomization 4.8 5.6 0.03 152 154 0.7 
2 days 3.7 4.3 0.04 161 162 0.7 
Long-term: dalteparin placebo dalteparin placebo 
4-7 weeks 2.4 2.2 0.3 162 137 <O.OOl 
3 months 2.4 2.1 0.2 162 136 CO.001 
Follow-up 6 mo 2.2 2.1 0.6 142 134 0.01 
1048-116 A Deadly Combination: Elevated Troponin I and 
Peripheral White Blood Cell Count Imply Poor 
Prognosis in Patients With Suspected Myocardial Injury 
Ali F. Sonel Chester B. Good, Mary E. Kelley, Lauren Wall, Jeffrey Whittle, Michael J. 
Fine, VA Pittsburgh Healthcare System, Center for Health Equity Research and 
Promotion, Pittsburgh, PA, University of Pittsburgh, Cardiovascular Institute, Pittsburgh, 
PA 
Background: Abnormal troponin values predict short and long-term cardiac events in 
patients with non-ST-segment elevation Ml (NSTEMI) and unstable angina (UA). White 
blood cell (WBC) elevations have also been reported to predict adverse events in the 
same population. The additive value of WBC over troponin levels is unknown. 
Methods: To determine the additive value of WBC counts to troponin I (Tnl). we pro- 
spectively studied 365 patients without ST-elevation, admitted with suspicion of Ml. Clini- 
cal information was determined by chart review. Patients were followed for 30.day 
endpoint of death or new MI. Elevated WBC was defined as >I 1 Wmn?. Manufacturer 
cut-off was used for abnormal Tnl. Univariate predictors of events were entered into a 
multivariable model. 
Results: Mean age was 66 +/- Il. During follow up events occurred in 36 patients 
(10.4%). Patients with events had hlgher mean WBC count compared to event free 
patients (12 +I- 6 vs. 9 +/-7, p=O.O15). Event rates were 4% wth both normal Trill and 
WBC, 14% with one being abnormal and 25% if both were abnormal (p<O.Ol). Significant 
univarlate predictors of events were elevated Tnl, elevated CKMB, elevated WBC, hemo- 
dynamic instability, pulmonary edema, age >64, ST-segment changes, and Canadian 
Cardiovascular Class III-IV at presentation 
